Vnitr Lek 2020, 66(4):e7-e16 | DOI: 10.36290/vnl.2020.074

Bleeding in portal hypertension

Tomáš Fejfar1, Tomáš Vaňásek1, Petr Hůlek1,2
1 II. interní gastroenterologická klinika LF UK a FN Hradec Králové
2 Katedra interních oborů LF OU Ostrava

Liver cirrhosis is the most common reason of clinically significant portal hypertension in the western countries. Portal vein or hepatic veins thrombosis is less common. Variceal bleeding is the most severe life threatening complication of portal hypertension. Appropriate treatment includes initial general management, fluid replacement and hemosubstitution, antibiotic prophylaxis, vasoactive medication and endoscopic treatment. Transjugular intrahepatic portosystemic shunt (TIPS) is standard option in case of first line treatment failure. Dedicated esophageal metal stent or balloon tamponade could be used as a bridge to the TIPS or in case of TIPS contraindication. Non selective beta-blockers and endoscopic therapy are used in primary and secondary prophylaxis.

Keywords: bleeding, portal hypertension, treatment.

Published: June 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fejfar T, Vaňásek T, Hůlek P. Bleeding in portal hypertension. Vnitr Lek. 2020;66(4):e7-16. doi: 10.36290/vnl.2020.074.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Šafka V. Portální hypertenze, patofyziologie portální hypertenze In: Hůlek P, Urbánek P (eds.). Hepatologie, 3. vydání. Praha: Grada 2018, 180-181.
    2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406-460. Go to original source... Go to PubMed...
    3. Fejfar T, Vaňásek T, Brůha R, et al. Léčba krvácení v důsledku portální hypertenze při jaterní cirhóze - aktualizace doporučených postupů ČHS ČLS JEP. Gastroent Hepatol 2017; 71: 105-116. Go to original source...
    4. De Franchis R, Baveno VI. Faculty Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015 ;63: 743-752. Go to original source... Go to PubMed...
    5. De Francis R et al. Portal hypertension IV: Proceedings of the Fourth Baveno International Konsensus Workshop. Blackwell Publishing Ltd., 2006. Go to original source...
    6. De Franchis R, et al. Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, 5th Edition. Wiley-Blackwell press. London; 2011. Go to original source...
    7. North Italian Endoscopic Club for Study and Treatment of Esophageal Varices. Prediction of the first variceal haemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicentre study. N Engl J Med 1988; 319: 983. Go to original source... Go to PubMed...
    8. D'Amico G, Pasta L, Morabito A et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014; 39: 1180-1193. Go to original source... Go to PubMed...
    9. Augustin S, Muntaner L, Altamirano JT, et al. Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis. Clin Gastroenterol Hepatol 2009; 7: 1347-1354. Go to original source... Go to PubMed...
    10. Carbonell N, Pauwels A. Sarfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40: 652-659. Go to original source... Go to PubMed...
    11. Villanueva C, Colomo A, Bosch et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368: 11-21. Go to original source... Go to PubMed...
    12. Bosch J, Thabut D, Albillos A et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomised, controlled trial. Hepatology 2008; 47: 1604-1614. Go to original source... Go to PubMed...
    13. Bendtsen F, D´Amico G, Rusch E, et al. Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials. J Hepatol 2014; 61: 252-259. Go to original source... Go to PubMed...
    14. Goulis J, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27: 1207-1212. Go to original source... Go to PubMed...
    15. Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-1661. Go to original source... Go to PubMed...
    16. Soares-Weiser K, Brezis M, Tur-Kaspa R, et al. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev 2002; 2: CD002907. Go to original source... Go to PubMed...
    17. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010; 8: CD002907. Go to original source... Go to PubMed...
    18. Hůlek P, Krajina A (eds.). Current Practice of TIPS. Hradec Králové: Published by Olga Štambergová 2001
    19. Brůha R, Mareček Z, Procházka V, et al. Double-Blind Randomized Multicenter Study Comparing the Efficacy and Safety of 10-Day to 5.Day Terlipressin Treatment of Bleeding Esophageal Varices. Hepato-Gastroenterology 2009; 56: 390-394. Go to PubMed...
    20. Merkel C, Gatta A, Bolognesi M, et al. Hemodynamic changes of systemic, hepatic and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 1988; 33: 1103-1109. Go to original source... Go to PubMed...
    21. Møller S, Hansen EF, Becker U, et al. Central and systemic haemodynamic effect of terlipressin in portal hypertensive patients. Liver 2000; 20: 51-59. Go to original source... Go to PubMed...
    22. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003; 1: CD002147. Go to original source...
    23. Wells M, Chande N, Adams P. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012; 35: 1267-1278. Go to original source... Go to PubMed...
    24. Yim SY, Seo YS, Jung CH, et al. Risk Factors for Developing Hyponatremia During Terlipressin Treatment: A Retrospective Analyses in Variceal Bleeding. J Clin Gastroenterol 2015; 49: 607-612. Go to original source... Go to PubMed...
    25. Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 1995; 22: 106-111. Go to original source... Go to PubMed...
    26. Moitinho E, Planas R, Banares R et al. Multicenter randomised controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001; 35: 712-718. Go to original source... Go to PubMed...
    27. Vilanueva C, Planella M, Arycil C, et al. Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. Am J Gastroenterol 2005; 100: 624-630. Go to original source... Go to PubMed...
    28. Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014; 60: 954-963. Go to original source... Go to PubMed...
    29. Svoboda P, Konečný M, Martínek A, et al. Acute upper gastrointestinal bleeding in liver cirrhosis patients. Biomedical Papers 2012; 165: 266-270. Go to original source... Go to PubMed...
    30. D'Amico G, Pietrosi G, Tarantino I, et al. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003; 124: 1277-1291. Go to original source... Go to PubMed...
    31. D'Amico G, Pagliaro L, Pietrosi G, et al. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhotic patients: a Cochrane meta-analysis. Cochrane Database Syst Rev 2010; 3: CD002233. Go to original source... Go to PubMed...
    32. Gralnek IM, Dumonceau JM, Kuipers JE, et al. Diagnosis and management of nonvariceal uppergastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: 1-46. Go to original source... Go to PubMed...
    33. Lo GH, Lai KH, Cheng JS, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997; 25: 1101-1104. Go to original source... Go to PubMed...
    34. Villanueva C, Piqueras M, Aracil C, at al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 2006; 45: 560-567. Go to original source... Go to PubMed...
    35. Vaňásek T. Endoskopické diagnostické a terapeutické metody. In: Hepatologie, 1. vydání. Praha: Grada Publishing 2010, 88-99.
    36. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014; 61: 642-659. Go to PubMed...
    37. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60: 715-735. Go to original source... Go to PubMed...
    38. Banares R, Albilos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002; 35: 609-615. Go to original source... Go to PubMed...
    39. Abraldes JG, Vilanueva C, Banares R, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008; 48: 229-236. Go to original source... Go to PubMed...
    40. D´Amico G, de Franchis R. Upper digestive bleeding in cirrhosis. Posttherapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599-612. Go to original source... Go to PubMed...
    41. Cardenas A, Gines P, Uritz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors and short-term prognosis. Hepatology 2001; 34: 671-676. Go to original source... Go to PubMed...
    42. Avgerinos A, Armonis A. Balloon tamponade technique and efficacy in variceal haemorrhage. Scand J Gastroenterol 1994; 29: (Suppl. 207): 11-16. Go to original source... Go to PubMed...
    43. Zehetner J, Shamiyeh A, Wayand W, et al. Results of a new method to stop acute bleeding from esophageal varices: implantation of a self-expanding stent. Surg Endosc 2008; 22: 149-152. Go to original source... Go to PubMed...
    44. Wright G, Lewis H, Hogan B, et al. A self-expanding metal stent for complicated variceal hemorrhage: experience at a single center. Gastrointest Endosc 2010; 71: 71-78. Go to original source... Go to PubMed...
    45. Fejfar T, Šafka V, Jirkovský V, et al. Danišův jícnový stent v terapii varikózního krvácení. Gastroent Hepatol 2013; 67: 98-103.
    46. Escorsell À, Pavel O, Cárdenas A, et al Variceal Bleeding Study Group. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology 2016; 63: 1957-1967. Go to original source... Go to PubMed...
    47. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjuglar intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996; 111: 138-146. Go to original source... Go to PubMed...
    48. Chau TN, Patch D, Chan YW, et al. "Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998; 114: 981-987. Go to original source...
    49. Krajina A, Hulek P, Fejfar T, et al. Quality improvement guidelines for Transjugular Intrahepatic Portosystemic shunt (TIPS). Cardiovasc Intervent Radiol 2012; 35: 1295-1300. Go to original source... Go to PubMed...
    50. Gluud LL, Krag A Banding ligation versus beta-blockers for primary prevention of oesophageal verices in adults. Cochrane Database Syst Rev 2012; 8: CD004544. Go to original source... Go to PubMed...
    51. Drastich P, Lata J, Petrtýl J, et al. Endoscopic variceal band ligation compared with propranolol for prophylaxis of first variceal bleeding. Annals of Hepatology 2011; 10: 142-149. Go to original source... Go to PubMed...
    52. Tripathi D, Hayes PC. Beta-blockers in portal hypertension: new developments and controversies. Liv Intern 2014; 34: 655-667. Go to original source... Go to PubMed...
    53. Ohnishi K, Nakayama T, Saito M et al. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am J Gastroenterol 1985; 80: 132-135.
    54. Mastai R, Bosch J, Navasa M, et al. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1987; 4: 71-79. Go to original source... Go to PubMed...
    55. Sinagra E, Perricone G, D´Amico M, et. al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther 2014; 39: 557-568. Go to original source... Go to PubMed...
    56. Akbas H, Ozden M, Kanko M, et al. Protective antioxidant effects of carvedilol in a rat model of ischaemia-reperfusion injury. J Int Med Res 2005; 33: 528-536. Go to original source... Go to PubMed...
    57. Hamdy N, Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol 2012; 261: 292-299. Go to original source... Go to PubMed...
    58. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236. Go to original source... Go to PubMed...
    59. Lo GH, Chen WC, Wang HM, et al. Randomized controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroentol Hepatol 2012; 27: 1681-1687. Go to original source... Go to PubMed...
    60. Vlachogiannakos J, Goulis J, Patch D, et al. Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis. Aliment Pharmacol Ther 2000; 14: 851-860. Go to original source... Go to PubMed...
    61. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-2261. Go to original source... Go to PubMed...
    62. Imperiale T, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001; 33: 802-807. Go to original source... Go to PubMed...
    63. Grace N, Lo GH, Nevens F, et al. Preventing rebleeding in 2010. In: De Franchis R et al. Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, 5th Edition. Wiley-Blackwell press. London 2044: 121-131. Go to original source...
    64. Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40: 793-801. Go to original source... Go to PubMed...
    65. Garcia-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 2370-2379. Go to original source... Go to PubMed...
    66. Garcia-Pagán JC, Di Pascoli M, Caca K et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013; 58: 45-50. Go to original source... Go to PubMed...
    67. Lo GH, Lai KW, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomised trial. Hepatology 2000; 32: 462-465. Go to original source...
    68. De la Pena J, Brullet E, Sanchez-Hernández E, et al. Variceal ligation plus nadolol compared with ligation for prophyla for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41: 572-578. Go to original source... Go to PubMed...
    69. Sersté T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refraktory ascites: a cross-over study. J Hepatol 2011; 55: 794-799. Go to original source... Go to PubMed...
    70. Sersté T, Melot C, Francoz C, et al. Deleterious effect of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017-1022. Go to original source... Go to PubMed...
    71. Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effect of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012; 61: 967-969. Go to original source... Go to PubMed...
    72. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2014; 60: 643-653. Go to original source... Go to PubMed...
    73. Garcia-Tsao J, et al. AASLD Practice Guidelines. Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. Hepatology 2007; 46: 922-938. Go to original source... Go to PubMed...
    74. Ryan BM, Stockbrugger RW, Ryan JM. A Pathophy¬siologic, Gastroenterologic and radiologic Approach to the Managament of gastric Varices. Gastroenterology 2004; 126: 1175-1189. Go to original source... Go to PubMed...
    75. Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992; 16: 1343-1349. Go to original source... Go to PubMed...
    76. Sarin SK, Kumar A. Gastric varices: profile, classification and management. Am J Gastroenterol 1989; 84: 1244-1249.
    77. Lo Gh, Lai Kh, Cheng JS, et al. A prospective randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001; 33: 1060-1064. Go to original source... Go to PubMed...
    78. Tan PC, Hou MC, Lin HC, et al. A randomized trial of endoscopic treatment of acute gastric variceal haemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology 2006; 43: 690-697. Go to original source... Go to PubMed...
    79. Tripathi D, Therapondos G, Jackson E, et al. The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations. Gut 2002; 51: 270-274. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.